03-01-05

ITU RECEPT

CASE ON/4-32344A



FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

5401543 834S Express Mail Label Number

FEBRUARY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

AVRAMIS ET AL.

APPLICATION NO: 10/505,399

FILED: AUGUST 19, 2004

FOR: COMBINATIONS OF (A) AN ATP-COMPETITIVE INHIBITOR OF

C-ABL KINASE ACTIVITY WITH (B) TWO OR MORE OTHER

ANTINEOPLASTIC AGENTS

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

LETTER CORRECTING OFFICIAL FILING RECEIPT

Sir:

The official filing receipt received in the above-identified application erroneously omitted one Applicant. Please issue a corrected filing receipt listing the Applicants as follows:

-- Applicant(s)

Ioannis Alexander Avramis, Sylmar, CA;

Vassilios Ioannis Avramis, Sylmar, CA --

A copy of the filing receipt with the correction noted is enclosed.

No fee is believed to be required by this request for a corrected filing receipt.

Respectfully submitted,

Novartis Corporate Intellectual Property One Health Plaza, Building 104 East Hanover, NJ 07936-1080

Date:

(862) 778-7852

Oona A. Jackson Attorney for Applicants Reg. No. 48,152



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P. Dox 1450 Alexandra, Virginia 22313-1450 www.uspto.gov

FILING OR 371 DRAWINGS TOT CLMS IND CLMS ATTY.DOCKET NO ART UNIT FIL FEE REC'D APPL NO. (c) DATE ON/4-32344A 14 10/505.399 1616 1006 08/19/2004

CONFIRMATION NO. 7262

FILING RECEIPT

OC0000000149991641

Date Mailed: 02/09/2005

1095 **NOVARTIS** CORPORATE INTELLECTUAL PROPERTY ONE HEALTH PLAZA 104/3 **EAST HANOVER, NJ 07936-1080**

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

loannis Alexander Avramis, Sylmar, CA; VASSILIOS TOANNIS AVRAMIS, SYLMAR, CA

Power of Attorney:

Lydia McNally-36214

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/EP03/02029 02/27/2003 which claims benefit of 60/360,197 02/28/2002

Foreign Applications

Projected Publication Date: To Be Determined - pending completion of Security Review

Non-Publication Request: No

Early Publication Request: No

Title

Combinations of (a) an atp-competitive inhibitor of c-acl kinase activity with (b) two or more other antineoplastic agents

Preliminary Class

514

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).